Johnson & Johnson’s Janssen Biotech has licensed global development and commercialisation rights to Genmab’s human CD38 monoclonal antibody daratumumab in a deal potentially worth US$1.1 B, including US$55 M upfront. The deal will also see Johnson & Johnson become the Danish company’s largest shareholder with a 10.73% equity stake. Daratumumab is currently in Phase I/II development for multiple myeloma but also has potential in other haematological cancers.